Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

"Faces" of the day:

Christina Flucher

Nicole Golob-Schwarzl

Saskia Hankel

Birgit Gallé

Aaroh Anand Joshi

Qishun Zhou

Vijaykumar Patra

Mario Scherkl

Benjamin Michel Rene Bourgeois

Sebastian Tschauner

Thomas Eichmann

Gabor Toth-Gayor

Niels Hammer

Tobias Madl

Georg Singer

Human-Friedrich Unterrainer

Harald Köfeler

Roland Malli

Gernot Reishofer

Slave Trajanoski

Peter Wolf

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Giannini, C; Capodanno, D; Toth, GG; Windecker, S; Schüpke, S; Blackman, DJ; Noble, S; Eltchaninoff, H; Fiorina, C; Chieffo, A; Bartorelli, AL; Schmidt, A; De, Backer, O; Gilard, M; Curtis, E; L'Official, G; Donal, E; Laroche, C; Prendergast, B; Petronio, AS; The, European, Valve, Durability, Tavi, Registry, Investigators, OB.
Long-term structural valve deterioration after TAVI: insights from the EORP ESC Valve Durability TAVI Registry.
EuroIntervention. 2025; 21(10):537-549 Doi: 10.4244/EIJ-D-24-00662 [OPEN ACCESS]
PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Schmidt Albrecht; Toth-Gayor Gabor
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: BACKGROUND: Valve durability is a key consideration as the patient population eligible for transcatheter aortic valve implantation (TAVI) expands to include lower-risk and younger individuals who are expected to live many years after the procedure. AIMS: This registry aimed to assess the incidence of long-term structural valve deterioration (SVD) beyond 5 years post-TAVI. METHODS: Consecutive living patients who underwent TAVI up until 2014 using any commercially available transcatheter heart valve (THV) at 22 participant centres were enrolled in the European Valve Durability TAVI Registry. All patients underwent comprehensive echocardiographic assessments (61% were evaluated independently by a central core laboratory) within 6 months of enrolment and at least 5 years post-TAVI; SVD was defined according to Valve Academic Research Consortium 3 definitions. RESULTS: A total of 597 patients (aged 79.6±7.1 years at the time of TAVI; 47.2% male, mean Society of Thoracic Surgeons score 5.0%) were included. At a median of 6.1 years of follow-up (interquartile range 5.2-7.3 years), the crude incidence of moderate/severe SVD was 9.5% (n=57; moderate: 6.2%, n=37; severe: 3.4%, n=20). Predictors of SVD identified by Cox regression analysis were use of an intra-annular THV (hazard ratio [HR] 38.44, 95% confidence interval [CI]: 10.8-136.3; p<0.001), a small THV size (HR 4.82, 95% CI: 2.42-9.60; p<0.001) and moderate/severe postprocedural paravalvular leak (HR 3.64, 95% CI: 1.59-8.32; p=0.002). CONCLUSIONS: The incidence of moderate/severe SVD during long-term follow-up after TAVI is low, with severe SVD being even rarer than moderate SVD. SVD occurs more frequently in patients treated with older-generation intra-annular valves and in those with small-sized THVs.
Find related publications in this database (using NLM MeSH Indexing): Humans - administration & dosage; Male - administration & dosage; Female - administration & dosage; Transcatheter Aortic Valve Replacement - adverse effects, methods; Aged - administration & dosage; Registries - administration & dosage; Aged, 80 and over - administration & dosage; Aortic Valve Stenosis - surgery; Aortic Valve - surgery, diagnostic imaging; Heart Valve Prosthesis - administration & dosage; Treatment Outcome - administration & dosage; Prosthesis Failure - administration & dosage; Risk Factors - administration & dosage; Time Factors - administration & dosage; Incidence - administration & dosage; Echocardiography - administration & dosage